SparingVision is pleased to announce that it will present a poster highlighting the Company’s recent research into ocular diseases and its lead gene therapy treatment, SPVN06, at the American Society of Gene and Cell Therapy (‘ASGCT’) 24th Annual Meeting

SparingVision is pleased to announce that it has presented three posters highlighting the Company’s recent research into ocular diseases and its lead gene therapy treatment, SPVN06 at the ARVO 2021 Annual Meeting. Details of the posters can be found below.

Adds unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa

Broadens SparingVision’s innovative genomic medicine pipeline to address both mid and late stages of rod-cone dystrophies with the added potential to combine both products

SparingVision’s management team will hold a webinar to discuss the news today at 16:00 CET/15:00 BST / 10:00 EDT - please find a link to this webinar here

An abstract on rod-derived cone viability factor (RdCVF) in pig models of Retinitis Pigmentosa (RP) has been accepted for a poster presentation at ASGCT 2021 Annual Meeting, to be held virtually on 11-14 May.

Three abstracts highlighting the company’s recent research into ocular diseases and its lead gene therapy treatment SPVN06 have been accepted for the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, to be held virtually from 1-7 May. 

SparingVision announces the conferences that its management team will be participating in in the first half of 2021.

Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development

Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board